Teladoc Health to Participate in Upcoming Investor Conference NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, and Mala Murthy, chief financial officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on Wednesday, June 11th, 2025, at 9:20 a.m. ET. A live audio webcast and replay of the presentation will be available at . About Teladoc HealthTeladoc Health empowers all people everywhere to live their healthiest lives by trans...
Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued inducement awards to two new employees. Effective June 1, 2025, in connection with commencing employment, two new non-executive employees of Teladoc Health were granted awards of restricted stock units covering an aggregate of 80,000 shares of Teladoc Health’s common stock, par value $0.001 per share. The restricted stock units vest, based on continued service to Teladoc ...
We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE)...
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first q...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.